Moderna MRNA endured a storm of fluctuating fortunes, experiencing both gains and losses. Positive news included the
FDA approving
Moderna's next-generation COVID vaccine, mNEXSPIKE, notably suited for adults 65 or older. This became Moderna's third FDA-approved product. Furthermore, Moderna's mixed flu and COVID mRNA shot was proven to outperform current vaccines in a considerable trial. However,
Health and Human Services (HHS) made a series of announcements cancelling funding orders valued in the millions for Moderna’s mRNA-1018 Avian Influenza Vaccine. Additional negative news came with Moderna withdrawing its FDA application for the flu/COVID combination vaccine with plans to resubmit later.
Robert F. Kennedy Jr. appeared in headlines causing further concern over Moderna's influenza vaccine and CDC pregnancy guidelines. Despite the setbacks, the company achieved a significant 98% success rate with the H5 flu vaccine despite funding loss, and it continues to drive the development of mRNA-based vaccines.
Moderna MRNA News Analytics from Fri, 25 Oct 2024 07:00:00 GMT to Sat, 31 May 2025 23:30:52 GMT -
Rating -7
- Innovation 4
- Information 8
- Rumor 1
